Doctors Raise Alarms Over Patients with Eating Disorders Using GLP-1 Weight Loss Drugs

One in eight American adults now takes a GLP-1 receptor agonist [1]. An estimated 30 million Americans will experience an eating disorder in their lifetime [2]. Where those two populations overlap, a clinical gray zone has emerged — one that no federal regulation, professional guideline, or pharmaceutical label adequately addresses.

GLP-1 drugs — including semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — work partly by suppressing appetite. For patients with obesity or type 2 diabetes, that mechanism is therapeutic. For patients with anorexia nervosa, bulimia, or a history of restrictive eating, it can be something else entirely: a pharmacological reinforcement of the very behaviors their treatment is trying to undo.

The Scale of Overlap

Binge eating disorder (BED) is the most common eating disorder in the United States, affecting an estimated 3.5% of women and 2.0% of men over their lifetimes [2]. Bulimia nervosa affects roughly 1.5% of women and 0.5% of men, while anorexia nervosa affects about 0.9% of women and 0.3% of men [2].

Source: ANAD / National Alliance for Eating Disorders (2024)

Data as of Dec 1, 2024CSV

Obesity, meanwhile, affects 42% of American adults [3]. The overlap between obesity and binge eating disorder is substantial — BED frequently presents alongside higher body weight, making patients eligible for GLP-1 prescriptions under standard BMI-based criteria. This creates a clinical paradox: the same patients who qualify for appetite-suppressing medication on the basis of their weight may also have an eating disorder that makes that medication risky.

Source: WHO Global Health Observatory

Data as of Dec 31, 2022CSV

There is no public registry tracking how many eating disorder patients are currently prescribed GLP-1 drugs. But the rapid expansion of direct-to-consumer telehealth platforms — which prescribe GLP-1s after brief online consultations — has made access easier than ever while making screening harder. As Aaron Keshen, a psychiatrist researching GLP-1s and eating disorders, has noted, there are "limitations to what clinicians can do in terms of screening and monitoring" in fast-paced clinical settings [1].

Different Disorders, Different Risks

The risk profile of GLP-1 use varies considerably across eating disorder diagnoses, and clinicians who treat these conditions say the public conversation often collapses distinct conditions into a single category.

Anorexia nervosa and atypical anorexia: For patients with restrictive eating disorders, GLP-1s pose the most straightforward danger. The drugs suppress hunger cues that eating disorder treatment specifically aims to rebuild. A case reported by National Geographic in 2025 illustrates the pattern: a woman treated for anorexia as a child was prescribed tirzepatide for diabetes and metabolic conditions. The medication appeared to "activate the past history of anorexia," according to her clinicians, prompting over-exercise and secret continued dosing even after her physician discontinued the prescription [1]. The National Association of Anorexia Nervosa and Associated Disorders (ANAD) notes that appetite suppression can "reinforce restrictive eating patterns" and that recovery from anorexia depends on reconnecting with hunger signals — exactly what GLP-1s are designed to blunt [4].

Bulimia nervosa: For patients with bulimia, GLP-1s introduce a different set of risks. The drugs' common gastrointestinal side effects — nausea, vomiting, and reduced appetite — can trigger or mask purging behaviors [4]. ANAD identifies GLP-1 use as contraindicated for patients with bulimia nervosa or subthreshold bulimia because the medications "could worsen the restrictive eating behaviors common in these conditions" [4].

Binge eating disorder: Here, the picture is more complicated — and more contested. Emerging clinical evidence suggests that semaglutide and liraglutide may reduce binge eating episodes and decrease food cravings [5]. A 2024 systematic review found that GLP-1 receptor agonists showed promise in reducing binge frequency, with semaglutide performing favorably compared to lisdexamfetamine and topiramate, two medications commonly prescribed for BED [5]. However, no GLP-1 currently holds FDA approval for binge eating disorder, and the existing studies are small-scale with methodological limitations [6].

The FDA Label Gap

The FDA label for semaglutide does not list eating disorders as a contraindication [1]. This omission has drawn scrutiny from clinicians and eating disorder specialists, though no formal regulatory petition for a label change has gained public traction as of mid-2026.

The absence of a contraindication does not reflect an affirmative finding of safety. No large-scale randomized controlled trial has specifically studied GLP-1 safety in eating disorder populations. The major semaglutide weight management trials (the STEP program) excluded patients with active eating disorders from enrollment, meaning the label's silence reflects a gap in data rather than evidence of safety [7].

A 2024 pharmacovigilance study using the FDA's Adverse Event Reporting System (FAERS) database identified statistically significant signals for eating disorder-related adverse events among GLP-1 users. Eating disorders showed a reporting odds ratio (ROR) of 1.57 (95% CI: 1.40–1.77), while binge eating had an ROR of 2.70, fear of eating 3.35, and self-induced vomiting 3.77 [8]. However, the absolute numbers were small — 21 reports of binge eating, 8 of fear of eating, and 7 of self-induced vomiting — and FAERS data is subject to reporting bias and cannot establish causation [8].

A separate 2023 FDA analysis found semaglutide associated with four times higher misuse reports compared to other GLP-1 drugs, along with more gastrointestinal and psychiatric adverse events [1].

The Case for GLP-1s in Binge Eating Disorder

Physicians who treat obesity argue that alarm over GLP-1s and eating disorders risks overgeneralizing the dangers of anorexia onto a heterogeneous patient population.

Jesse Richards, an obesity specialist at the University of Oklahoma, is among those who emphasize the distinction. Binge eating disorder is the most common eating disorder, and obesity is a recognized comorbidity. Patients with both conditions face compounding health risks — cardiovascular disease, type 2 diabetes, metabolic syndrome — that GLP-1s directly address [1].

The neurobiological rationale for GLP-1s in BED treatment extends beyond appetite suppression. Preclinical studies show that GLP-1 receptor agonists reduce food-seeking behavior and modulate dopamine signaling in reward circuits — the same neural pathways implicated in binge eating [5]. A 2025 study found that participants on semaglutide reported fewer food cravings, especially for carbohydrates and sugar, and described remaining cravings as less intense and easier to resist [9].

Amanda Lightbody, founder of The Rainbow Crosswalk, has spoken publicly about using Ozempic alongside therapy for binge eating disorder, reporting reduced cravings for processed foods [1]. Her case reflects a subset of patient experiences where GLP-1s complement — rather than replace — psychological treatment.

The Obesity Medicine Association, in a 2025 joint advisory with the American College of Lifestyle Medicine, the American Society for Nutrition, and The Obesity Society, stopped short of contraindicating GLP-1 use in all eating disorder patients. Instead, the advisory recommended that patients with a history of eating disorders be referred to both an obesity medicine specialist and an eating disorders specialist, while identifying "restrictive eating disorder" specifically as a general contraindication [10].

Where Professional Bodies Stand

The medical establishment's response has been fragmented.

ANAD recommends "extreme caution" and a multidisciplinary team approach — physician, therapist, and dietitian — before any patient with an eating disorder history starts a GLP-1 [4]. The organization has warned that "many weight loss specialists may have limited training in eating disorders," creating diagnostic gaps where atypical anorexia or non-purging bulimia may be misclassified as binge eating disorder [4].

The 2025 joint advisory from the Obesity Medicine Association and three other professional societies acknowledged eating disorder screening as part of baseline assessment before GLP-1 initiation, recommending evaluation of "usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions" [10]. But it framed this as advisory, not mandatory.

No comprehensive clinical guideline from the American Psychiatric Association specifically addressing GLP-1 use in eating disorder patients has been published as of mid-2026. Formal guidelines from major psychiatric organizations appear to still be in development [7].

This gap means prescribing decisions are largely left to individual clinicians — many of whom, particularly in primary care and telehealth settings, lack specialized training in eating disorder assessment.

The Telehealth and Screening Problem

The growth of direct-to-consumer telehealth platforms has made GLP-1s more accessible while potentially bypassing the kind of comprehensive evaluation that eating disorder experts recommend.

No national protocol currently requires eating disorder screening before GLP-1 prescribing [1]. While clinical best practice calls for a comprehensive history that includes eating disorder assessment, the standard varies widely across providers and platforms. Some telehealth services conduct evaluations via brief questionnaires; others rely primarily on BMI and basic lab work [11].

The financial incentives are significant. GLP-1 drugs generated $131.9 billion in U.S. prescription spending in 2025, accounting for 14% of all drug spending nationally [12]. The global market is projected to reach $132.79 billion by 2035 [13]. For telehealth platforms competing for patients, lengthy psychiatric screenings represent both a cost and a potential barrier to conversion.

The liability question remains largely untested in court. If a patient with an undiagnosed eating disorder obtains a GLP-1 through a telehealth platform and suffers harm — hospitalization from severe restriction, cardiac complications, refeeding syndrome — the prescribing provider's failure to screen could become the basis for a malpractice claim. But with no national standard of care explicitly requiring such screening, the legal landscape is uncertain.

What Happens When Patients Stop

For patients without eating disorders, GLP-1 discontinuation commonly leads to weight regain. A meta-analysis published in 2025 found that weight tends to return after stopping therapy, with fat mass recovering preferentially over lean mass — a pattern researchers describe as sarcopenic obesity [14].

For patients with eating disorders, the stakes of discontinuation are different. Appetite suppression can mask restrictive symptoms, making a patient appear "successful" while the underlying disorder progresses [15]. When the medication stops and hunger returns, patients may experience what clinicians describe as a destabilizing cycle: weight loss followed by regain, then shame, then renewed attempts at restriction [15].

ANAD estimates that approximately two-thirds of weight lost on GLP-1s returns within one year of discontinuation [4]. For someone whose relationship with food and body weight is already pathological, that rebound can trigger full relapse.

The psychological dependence question is distinct from physical dependence. GLP-1s are not considered addictive in a pharmacological sense. But for a patient with a restrictive eating disorder who has come to rely on chemical appetite suppression as a coping mechanism, the return of normal hunger can feel like losing control — a core fear in anorexia and related conditions [15].

Research on post-discontinuation psychological trajectories in eating disorder populations remains "insufficiently studied," according to a 2025 review, with most discontinuation research focusing on metabolic and weight outcomes rather than psychiatric ones [14].

A Research Boom, A Guidance Lag

Academic interest in the intersection of GLP-1s and eating disorders has surged. Research publications on the topic have grown from 129 papers in 2011 to 2,402 in 2025, with 917 already published in the first half of 2026 [16].

Source: OpenAlex

Data as of Jan 1, 2026CSV

But this research boom has not yet translated into clear clinical guidance. The gap between what researchers are studying and what practitioners on the ground can act on remains wide.

Susan McElroy, a psychiatrist at the University of Cincinnati College of Medicine who studies eating disorders and obesity, represents the camp calling for nuance rather than blanket alarm. The challenge, she and others argue, is developing screening tools and clinical pathways that can distinguish between patients who might benefit from GLP-1s (those with BED and comorbid obesity) and those who could be harmed (those with active or historical restrictive disorders) — and implementing those tools in the rushed, high-volume settings where most GLP-1 prescriptions originate [1].

Samantha DeCaro of the Renfrew Center, a national eating disorder treatment program, has emphasized that the conversation must account for the full spectrum of eating disorders rather than treating them as a monolith. A medication that reduces binge frequency in one patient may trigger dangerous restriction in another — and the current prescribing infrastructure is not built to tell the difference [1].

What Would Have to Change

Several concrete steps have been proposed by researchers and clinicians:

Standardized screening: A validated, brief eating disorder screening tool that can be integrated into primary care and telehealth workflows before GLP-1 prescribing. The tools exist — the SCOFF questionnaire, the EDE-Q — but their use is not required or standardized [4].

Label revision: Adding eating disorder-related warnings to GLP-1 labels, even if a formal contraindication is not supported by current evidence. This would at minimum alert prescribers to the risk [8].

Professional guidelines: Comprehensive clinical guidance from the American Psychiatric Association or equivalent bodies, specifically addressing GLP-1 use across the eating disorder spectrum [7].

Research investment: Large-scale, prospective studies examining GLP-1 safety and efficacy specifically in eating disorder populations — studies that the major clinical trials have so far excluded by design [5].

Until those steps are taken, the current situation persists: a class of medications that suppresses appetite being prescribed to millions of Americans, with no systematic effort to determine which of those patients have a condition that makes appetite suppression dangerous.